Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
BOLD
Boundless Bio, Inc.
Lead programs BBI-355, BBI-825, and BBI-940 are oral small-molecule therapeutics (CHK1 inhibitor, RNR inhibitor, and kinesin degrader), representing the core product category of Oral Small Molecule Therapeutics.
|
$27.76M |
$1.25
-0.40%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$27.72M |
$3.45
+1.02%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$27.45M |
$0.65
-4.05%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$27.25M |
$0.65
+1.25%
|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$26.95M |
$1.03
-2.36%
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$26.91M |
$0.29
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$26.37M |
$2.70
-2.17%
|
|
PLUR
Pluri Inc.
PluriCDMO provides cell-therapy manufacturing services, generating revenue and serving as a core business line.
|
$26.26M |
$3.15
+3.28%
|
|
IKNA
Ikena Oncology, Inc.
ImageneBio's lead asset IMG-007 is a monoclonal antibody targeting OX40 for immunological/inflammatory diseases, aligning with Immunology Therapeutics.
|
$26.26M |
$6.53
|
|
MODD
Modular Medical, Inc.
MODD directly manufactures insulin pumps (MODD1 and Pivot), a core medical device product category categorized under Medical Devices & Biometrics.
|
$26.26M |
$0.49
+2.87%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$26.21M |
$0.60
+2.54%
|
|
HBIO
Harvard Bioscience, Inc.
HBIO generates recurring revenue from consumables used with its medical devices and bioproduction platforms (biochips, reagents, etc.).
|
$26.15M |
$0.58
+0.71%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$26.02M |
$1.97
+1.03%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$25.93M |
$0.33
+9.43%
|
|
KPEA
Kun Peng International Ltd.
The business includes health care equipment-based services and devices, aligning with medical devices & equipment.
|
$25.60M |
$0.06
|
|
HOWL
Werewolf Therapeutics, Inc.
Werewolf Therapeutics develops conditionally activated immunotherapies for cancer, aligning with Biotech - Oncology.
|
$25.12M |
$0.55
-0.15%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$24.87M |
$1.53
+0.66%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$24.06M |
$6.87
+8.45%
|
|
IRIX
IRIDEX Corporation
IRIDEX directly designs, manufactures and sells ophthalmology devices (laser platforms, delivery systems) for eye diseases.
|
$23.96M |
$1.41
+4.44%
|
|
ZJYL
Jin Medical International Ltd.
The company designs, manufactures, and sells rehabilitation medical devices and biometrics-oriented equipment.
|
$23.87M |
$0.17
+14.72%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$23.78M |
$1.31
-4.71%
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$23.53M |
$0.03
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$23.42M |
$1.81
+3.12%
|
|
EKSO
Ekso Bionics Holdings, Inc.
Product portfolio includes Ekso Indego Personal and EksoNR, both medical devices used for rehabilitation and mobility assistance.
|
$23.14M |
$8.84
+3.39%
|
|
PIII
P3 Health Partners Inc.
Healthcare Services & Facilities
|
$23.00M |
$3.39
+2.73%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$22.89M |
$20.55
+2.04%
|
|
MLSS
Milestone Scientific Inc.
Direct dental equipment manufacturing (DPS-based systems and related dental devices) as the dental segment is a core business.
|
$22.55M |
$0.29
-0.66%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$22.43M |
$0.94
+1.16%
|
|
RVP
Retractable Technologies, Inc.
Core product category directly manufactured and sold: passive-safety syringes designed to prevent needlestick injuries.
|
$21.73M |
$0.72
+0.67%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$21.50M |
$1.71
-1.16%
|
|
WETH
Wetouch Technology Inc.
Medical applications revenue suggests involvement as a component provider in medical devices, i.e., Medical Device Components.
|
$21.24M |
$1.81
+1.97%
|
|
FEMY
Femasys Inc.
Femasys manufactures medical devices and biometrics for women's reproductive health (FemBloc, FemaSeed, FemVue, etc.).
|
$21.19M |
$0.65
+1.67%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$20.52M |
$1.00
+0.76%
|
|
NSYS
Nortech Systems Incorporated
Medical Device Components manufacturing and assembly for regulated markets.
|
$20.48M |
N/A
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$20.37M |
$0.66
-1.07%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Monoclonal antibody therapeutics tag reflects LIMN's lead anti-CD47 antibody program as a targeted biologic for cancer.
|
$20.01M |
$0.75
-3.68%
|
Showing page 31 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
